Promoted Content
Promoted Content

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Axon Neuroscience

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CYPRUS Cyprus

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              AI-Driven Evolution

              Participation Not Confirmed

              Update your events

              Axon Presented Positive Phase II Trial Results of AADvac1 at AAT-AD/PD 2020

              Contact the Supplier

              Lead Product(s): AADvac1

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 03, 2020

              Details:

              A highly significant impact on neurodegeneration was shown on brain proteins in plasma - Neurofilament Light Chain, and CSF - Tau and p-Tau, and Diffusion Tensor Imaging.

              PharmaCompass__DigitalAd